BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33283635)

  • 1. Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study.
    Gallacher D; Kimani P; Stallard N
    Med Decis Making; 2021 Jan; 41(1):37-50. PubMed ID: 33283635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrapolating Parametric Survival Models in Health Technology Assessment Using Model Averaging: A Simulation Study.
    Gallacher D; Kimani P; Stallard N
    Med Decis Making; 2021 May; 41(4):476-484. PubMed ID: 33626961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
    Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
    BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
    Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
    BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
    Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
    Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
    Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
    Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.
    Che Z; Green N; Baio G
    Med Decis Making; 2023 Apr; 43(3):299-310. PubMed ID: 36314662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer.
    Connock M; Hyde C; Moore D
    Pharmacoeconomics; 2011 Oct; 29(10):827-37. PubMed ID: 21770482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
    Bakker LJ; Thielen FW; Redekop WK; Groot CU; Blommestein HM
    BMC Med Res Methodol; 2023 May; 23(1):132. PubMed ID: 37248477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.
    Kearns B; Stevenson MD; Triantafyllopoulos K; Manca A
    Med Decis Making; 2022 Oct; 42(7):945-955. PubMed ID: 35769004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
    Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
    Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
    Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
    Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
    Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
    Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
    Gallacher D
    BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
    Monnickendam G
    Value Health; 2024 Feb; ():. PubMed ID: 38428815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs.
    van Oostrum I; Ouwens M; Remiro-Azócar A; Baio G; Postma MJ; Buskens E; Heeg B
    Value Health; 2021 Sep; 24(9):1294-1301. PubMed ID: 34452709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.
    Kearns B; Stevens J; Ren S; Brennan A
    Pharmacoeconomics; 2020 Feb; 38(2):193-204. PubMed ID: 31761997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.